Showing 971-980 of 1097 results for "".
- Sex and the City's Kristin Davis Partners with Coolsculpting for Denim Denial Programhttps://modernaesthetics.com/news/sex-and-the-citys-kirstin-davis-partners-with-coolsculpting-for-denim-denial-program/2472005/"Sex and the City” star Kristin Davis, is partnering with CoolSculpting for the new "Denim Denial" consumer program.Denim Denial recognizes that every woman has a pair of jeans on the top shelf of her closet or tucked away in a bottom drawer but is holding on to them with the
- Recros Medica Unveils the Nuvellus Brand for Its Novel Rotational Fractional Resection Technologyhttps://modernaesthetics.com/news/recros-medica-unveils-the-nuvellus-brand-for-its-novel-rotational-fractional-resection-technology/2472023/Recros Medica, Inc. is unveiling the Nuvellus brand at this week’s American Society of Plastic Surgery meeting. The company will display at booth #1264, where it will introduce Nuvellus as an innovative, minimally-invasive surgical procedure in develop
- New Cutera Survey Results Help Define Body Contouring Markethttps://modernaesthetics.com/news/new-cutera-survey-helps-define-body-contouring-market/2472026/One third of Americans opt for body sculpting treatments to look better naked, according to a new survey from Cutera, Inc. The survey results we
- ASPS Members Identify Key Plastic Surgery Trendshttps://modernaesthetics.com/news/asps-members-identify-key-plastic-surgery-trends/2472027/Breast augmentation, tummy tucks and liposuction will be the three most popular plastic surgery procedures in 2019, plastic surgeons predict. With regard to minimally invasive procedures, Botox still leads the way as the most anticipated request, followed by fillers, chemical peels, laser
- Galderma Launches "Face Your Hands" Campaign with Celebrity Manicuristhttps://modernaesthetics.com/news/galderma-launches-face-your-hands-campaign-with-celebrity-manicurist/2472030/Galderma Laboratories, L.P.,’s Restylane® Lyft is partnering with celebrity manicurist Deborah Lippmann for the "Face Your Hands" campaign, which aims to educate women on the steps they can take to achieve more youthful hands. A
- Special Report: Behind Allergan's and Bonti's Headline-Making Dealhttps://modernaesthetics.com/news/special-report-behind-allergans-and-bontis-headline-making-deal/2472032/The race was on. After years of dormancy in the neuromodulator category, at least three novel toxins— Evolus’ DWP-450, Revance’s daxibotulinumtoxinA, and Bonti’s EB-001—were coming down the pike. Industry watchers were abuzz with predictions about which toxin
- Allergan Shares Results of Higher Dose Botox Cosmetic for the Treatment Glabellar Lineshttps://modernaesthetics.com/news/allergan-share-results-of-higher-dose-botox-cosmetic-for-the-treatment-glabellar-lines/2472035/Allergan plc clinical study results of higher doses of Botox Cosmetic compared to Botox Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines. Allergan conducted this trial to evaluate the duration of effect and safety of Botox
- ASDS 2018 Survey: Close to 70 percent of Consumers Thinking About Cosmetic Treatmentshttps://modernaesthetics.com/news/asds-2018-survey-close-to-70-percent-of-consumers-are-thinking-about-cosmetic-treatments/2472034/Almost 70 percent of consumers are considering a cosmetic treatment, and more than half would prefer to pay more up front to lower their annual skin care costs, according to the 2018 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmeti
- Candela Acquires Ellipsehttps://modernaesthetics.com/news/candela-acquires-ellipse/2472039/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Evolus Resubmits BLA for DWP-450 Ahead of Schedulehttps://modernaesthetics.com/news/evolus-resubmits-bla-for-dwp-450-ahead-of-schedule/2472049/Evolus has resubmitted its Biologics License Application (BLA) for its lead product candidate, DWP-450 (prabotulinumtoxinA), to the FDA. The resubmission follows the receipt of a Complete Response Letter (“CRL”) from the FDA in May 2018 which necessita